SPAGN (Sarcoma Patients Global Net) invited PAWS-GISTs Patient Director to speak about the importance of patient involvement in Health Technology Assessment (HTA), at the European Society of Medical Oncology (ESMO) conference in Switzerland, as part of the Patient Advocacy track.
During the past fourteen years, Jayne has represented GIST patients in numerous NICE and Scottish Medicines consortium appraisals of new treatments in the UK.
Thankfully the UK’s drug appraisal authorities really value patient input. Real life experience both of GIST cancer and the drug being appraised have been and are vital components of the decision-making process.
Not all HTA systems in other countries facilitate patient input in this way.